ASCENTAWITS
Ascentawits focuses on developing small molecule targeted conjugated anti-tumor drugs. The company utilizes specific tumor micro-environments to carry out independent innovative drug designs and screening for the development of new anti-tumor drugs.
ASCENTAWITS
Industry:
Biotechnology Medical Pharmaceutical Product Research
Founded:
2017-01-01
Address:
Shenzhen, Guangdong, China
Country:
China
Website Url:
http://www.ascentawits.com
Total Employee:
51+
Status:
Active
Contact:
0755-27888161
Total Funding:
200 M CNY
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Mobile Non Scaleable Content Pound Sterling Japanese Yen
Similar Organizations
Doublle Bioproduct
Doublle Bioproduct focuses on the research and development of anti-tumor drugs.
Etern
Etern is a biopharma company.
GeneFrontier
Gene Frontier took a new step as a member of the Kaneka Group.
Pro-Cure Therapeutics
Pro-Cure Therapeutics is focused on developing drugs targeted against cancer stem cells.
Stempeutics Research
Stempeutics Research focuses on developing and commercializing novel therapeutics based on adult stem cells.
Tyercan
Tyercan focuses on the research and development of innovative targeted anti-cancer and immunosuppressive drugs.
Investors List
Sangel Capital
Sangel Capital investment in Series A - Ascentawits
CICC
CICC investment in Series A - Ascentawits
Kangchengheng Touzi
Kangchengheng Touzi investment in Series A - Ascentawits
Cowin Capital
Cowin Capital investment in Series A - Ascentawits
Shenzhen Guozhong Venture Capital Management
Shenzhen Guozhong Venture Capital Management investment in Series A - Ascentawits
Essence Capital
Essence Capital investment in Series A - Ascentawits
Kangchengheng Touzi
Kangchengheng Touzi investment in Series A - Ascentawits
BGI Co-Win
BGI Co-Win investment in Series A - Ascentawits
Official Site Inspections
http://www.ascentawits.com
- Host name: 120.78.166.66
- IP address: 120.78.166.66
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Ascentawits"
深圳艾欣达伟医药科技有限公司
Global Pioneer of Small Molecule-Drug Conjugates. 全球小分子靶向偶联药物开拓者See details»
Ascentawits - Crunchbase Company Profile & Funding
Organization. Ascentawits . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Ascentawits focuses on developing small molecule targeted conjugated anti-tumor drugs. …See details»
Ascentawits Pharmaceuticals Ltd. - Drug pipelines, Patents, Clinical ...
Explore Ascentawits Pharmaceuticals Ltd. with its drug pipeline, therapeutic area, technology platform, 8 clinical trials, 2 news, and 5 literature, Disease Domain:Neoplasms, Endocrinology …See details»
Ascentawits Pharmaceuticals - Company Profile - Tracxn
Nov 27, 2024 Shenzhen Ascentawits Pharmaceuticals is involved in the development of anti-tumor drugs. The company uses a tumor microenvironment for prodrug design and screening …See details»
ASCENTAWITS, A World Intellectual Property Organization …
ASCENTAWITS is a WIPO trademark and brand of ASCENTAWITS PHARMACEUTICALS, LTD., Room 1003, 10th Floor, Building 10,, Biomedical Innovation Industrial Park,, No.14 Jinhui …See details»
Ascentawits Pharmaceutical - PitchBook
Ascentawits Pharmaceutical General Information Description. Developer of anti-tumor drugs. The company utilizes specific tumor micro-environments to carry out independent innovative drug designs and screening for the development of …See details»
Ascentawits Pharmaceuticals - Products, Competitors, Financials ...
Ascentawits Pharmaceuticals is a company focused on the development of small molecule-drug conjugates within the pharmaceutical industry. Use the CB Insights Platform to explore …See details»
Ascentawits - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Feb 11, 2021: Series A - …See details»
AST-004 (Ascentawits) - Drug Targets, Indications, Patents - Synapse
AST-004 (Ascentawits), Initially developed by Ascentawits Pharmaceuticals Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms,Digestive System Disorders, …See details»
Ascentawits - Tech Stack, Apps, Patents & Trademarks - Crunchbase
The intellectual property of Ascentawits includes 31 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category, according to IPqwery. Additionally, Ascentawits has …See details»
ASCENTAWITS Trademark of ASCENTAWITS PHARMACEUTICALS, …
Mar 31, 2020 Education services, namely, training educators in the field of science, technology, engineering and mathematics (STEM) curriculum, teaching methods and providing curricula in …See details»
Ascentawits Asset Profile | Preqin
Based in Shenzhen, China, and established in 2014, Ascentawits is a biotechnology company that focuses on the development of tumor drugs. It has established ...See details»
Ascentawits self-developing first-in-class drugs - EYESHENZHEN
Ascentawits Pharmaceuticals Ltd., located in Pingshan, Shenzhen, is engaged in the R&D of small-molecule drug conjugates, a promising approach for targeted cancer therapies. …See details»
Ascentawits Pharmaceuticals Ltd. (深圳艾欣达伟医药科技有限公司) …
了解Ascentawits Pharmaceuticals Ltd. (深圳艾欣达伟医药科技有限公司)公司的药物管线，治疗领域，技术平台，以及它的8项临床试验, 63篇新闻和5篇文献，疾病领域:肿瘤，内分泌与代谢疾 …See details»
AST-006 (Ascentawits) - Drug Targets, Indications, Patents - Synapse
AST-006 (Ascentawits), Initially developed by Ascentawits Pharmaceuticals Ltd., Now, its global highest R&D status is Phase 1, Therapeutic Areas: Neoplasms,Endocrinology and Metabolic …See details»
Ascentawits - Crunchbase
Ascentawits focuses on developing small molecule targeted conjugated anti-tumor drugs.See details»
Ascentawits self-developing first-in-class medicines
Oct 26, 2023 Ascentawits now has a 1,400-square-meter R&D center in Pingshan with over 30 professionals engaged in synthesis, testing and production for first-in-class drugs. The center …See details»
Company self-developing first-in-class drugs _英文报
2023-10-26 08:53 Shenzhen Daily : Cao Zhen. [email protected]. KNOWING that a fund for Shenzhen’s biomedicine industry, amounting to 5 billion yuan (US$684.8 million) for Phase …See details»
Series A - Ascentawits - 2021-02-11 - Crunchbase
Organization Name . Ascentawits . Announced Date Feb 11, 2021; Closed On Date Feb 11, 2021; Funding Type Series A; Funding Stage ... Recent News. Edit Recent News Section. News • …See details»
Ascentawits self-developing first-in-class drugs - EYESHENZHEN
Ascentawits now has a 1,400-square-meter R&D center in Pingshan with over 30 professionals engaged in synthesis, testing and production for first-in-class drugs. The center has carried out …See details»